Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what the science actually supports before you trust the answer.
Press Enter ↵ to search evidence
Explore by Goal
"The first principle is that you must not fool yourself — and you are the easiest person to fool."
- Richard Feynman
Quick Explanation
Copied
Prospective GBM liquid-biopsy study design (CSF + plasma, multi-analyte, BBB-aware)
A rigorous prospective study should (1) compare CSF vs plasma where CSF is expected to perform better for glioblastoma monitoring (reviewed across liquid-biopsy modalities), (2) pre-specify performance metrics and harmonized pre-analytics/assays to avoid assay variability and low-abundance artifacts, and (3) include longitudinal sampling to test whether cfDNA/EV classifiers track radiographic tumor burden and outcomes.
Evidence anchors: review of GBM liquid-biopsy challenges/standardization () and longitudinal CSF-reservoir cfDNA detectability with radiographic correlation ().
Long Explanation
Design Experiments: Prospective GBM Liquid Biopsy Study
Goal: create a prospective, longitudinal, multi-analyte study that tests whether CSF and plasma liquid-biopsy signals associate with tumor burden, diagnostic/monitoring performance, and survival/immune-linked biology in IDH-wildtype GBM—while actively addressing known blindspots (BBB effects, assay heterogeneity, low analyte abundance, confounding, and lack of standardization).
Key risk-aware rationale from the included sources: liquid biopsy faces BBB yield limits, marker heterogeneity, pre-analytical variability, and insufficient harmonization/validation ().
This study therefore pre-specifies sampling/assay harmonization and uses longitudinal endpoints rather than one-time discrimination.
1) Evidence-anchored starting points (numbers you can turn into endpoints)
Source: cfDNA detected in 53/55 (94%) CSF samples in a GBM CSF-reservoir longitudinal workflow ( ).
2) Study question & hypothesis space (what to test prospectively)
Primary endpoints (pre-specified)
Monitoring association: longitudinal CSF cfDNA concentration vs radiographic tumor burden (test correlation/trajectory concordance), motivated by reported radiographic correlation in CSF-reservoir sampling ().
Diagnostic triage performance: prospective sensitivity/specificity for detecting GBM (and separating GBM from non-GBM) using a multi-analyte plasma EV classifier and/or CSF cfDNA readouts. (Use the reported EV ML performance as a benchmark, but require independent prospective validation to reduce overfitting risk.) ( ).
Survival stratification linked to gut microbiome balance (Bacteroidaceae/Lachnospiraceae ratio) in IDH-wildtype GBM, using the reported hazard ratio as effect-size prior for sample size planning (but treat as correlative until replicated). ( ).
Immune remodeling readouts (tumor CD68/CD3/CD8 infiltration patterns) tested against microbiome-defined subgrouping to ensure that biomarker signals are not merely reflecting unrelated systemic shifts. ().
3) Visual workflow: what to do, when, and what it answers
Design logic tied to included evidence: (a) CSF sampling workflows have shown high cfDNA detectability and radiographic burden correlation (), while (b) liquid-biopsy review emphasizes BBB-yield variability and the need for harmonized protocols ().
4) Assay/biomarker modules to include (and why)
Important skepticism: the “evidence anchor” values above are drawn directly from the included source metrics ( ). Units differ by module, so this chart is for priority framing, not for quantitative pooling.
5) Statistical analysis plan (bias-aware, falsifiable)
Core analysis ideas grounded in the sources
Longitudinal coupling: quantify whether cfDNA levels track radiographic tumor burden (correlation/trajectory concordance), because the CSF-reservoir source reports such a link (p<0.01) ().
Prospective classifier validation: evaluate EV-based ML performance in held-out prospective folds / external cohorts; ML can overfit small, heterogeneous datasets, and the included source explicitly notes the need for independent validation ().
Confounding controls: for microbiome associations, use covariate adjustment because the reported microbiome survival effect was described as independent of age, MGMT methylation, and extent of resection (). Also pre-specify how diet/antibiotic exposure is handled (not fully controlled in the source, per its blindspots), to avoid residual confounding ().
6) Planned “falsification tests” (how this study could fail)
These are derived from the included sources’ stated limitations/blindspots: standardized, sufficiently powered prospective validation is required; assay variability/BBB yield and small cohorts threaten reproducibility; ML needs independent validation; microbiome effects may reflect confounding and lack replication ( ).
Sampling strategy: include serial CSF and plasma collections for each participant; prioritize CSF for longitudinal cfDNA detectability and tumor-burden tracking given reported performance ().
Pre-analytical harmonization: pre-specify collection tubes, processing time windows, and storage to reduce assay variability; this is strongly motivated by the liquid-biopsy review’s emphasis on pre-analytical factors and lack of standardized protocols ().
Multi-analyte modeling: combine EV features (e.g., CD9+ EV subsets reported as key discriminators) with cfDNA metrics for triage; but keep model training strictly separated from evaluation to avoid overfitting ().
Microbiome/immune add-on (optional secondary cohort): collect stool and tumor tissue when feasible to test the reported Bacteroidaceae/Lachnospiraceae and immune infiltration associations; treat as hypothesis-generating until replicated ().
It will transform the provided source metrics into a pre-registered endpoint matrix and plots, then automatically generate a minimal analysis checklist for longitudinal correlation vs prospective classifier validation.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
“Plasma alone will substitute for CSF in monitoring GBM.” This is less supported because the review emphasizes BBB effects and lower yield/variability issues for plasma, while the CSF-reservoir workflow shows strong detectability and radiographic correlation in the provided data ().
“Microbiome–survival associations are directly measurable via circulating cytokines.” Source blindspots indicate no consistent reflection in circulating cytokines/metabolites, so the cytokine-only mechanistic shortcut is less plausible ().
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Keep Exploring
Analysis 
Hypothesis Graveyard
Potential Experiments
Discussion